<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00295412</url>
  </required_header>
  <id_info>
    <org_study_id>5077-99904</org_study_id>
    <nct_id>NCT00295412</nct_id>
  </id_info>
  <brief_title>The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients</brief_title>
  <official_title>The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Montréal</source>
  <brief_summary>
    <textblock>
      The lifetime of substance use disorders in schizophrenia is close to 50%. Substance abuse in&#xD;
      schizophrenia is associated with negative consequences. Unfortunately, there no clear&#xD;
      guidelines for the pharmacological treatment of this dual diagnosis population. Preliminary&#xD;
      results suggest that second-generation antipsychotic drugs (mainly clozapine) may relieve&#xD;
      drug cravings in schizophrenia. We performed a 12-week pilot study to evaluate the impact of&#xD;
      quetiapine, a second-generation antipsychotic, on substance abuse parameters, psychiatric&#xD;
      symptoms and side effects in patients schizophrenia and comorbid substance use disorders. Our&#xD;
      expectation was a 20 % decrease in drug cravings from baseline to end-point.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Schizophrenia</condition>
  <condition>Substance Use Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with as schizophrenia spectrum disorder&#xD;
&#xD;
          -  Patients with a comorbid substance use disorder&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients already on quetiapine or clozapine&#xD;
&#xD;
          -  Patients hospitalized or acutely ill&#xD;
&#xD;
          -  Total score lower than 65 on the PANSS&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Female subjects of childbearing potential without adequate contraception&#xD;
&#xD;
          -  Abnormal liver function (hepatic enzymes more than 3 times the upper normal limits)&#xD;
&#xD;
          -  Any clinically meaningful unstable renal, hepatic, cardiovascular, respiratory,&#xD;
             cerebrovascular disease or other serious, progressive physical disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel Stip, Md, MSc, CSPQ</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche Fernand-Seguin, Hôpital Louis-H Lafontaine, Departement of Psychiatry, Faculty of medicine, University of Montreal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de recherche Fernand-Seguin</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1N 3V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>February 21, 2006</study_first_submitted>
  <study_first_submitted_qc>February 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2006</study_first_posted>
  <last_update_submitted>February 21, 2006</last_update_submitted>
  <last_update_submitted_qc>February 21, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

